Dr James Short shares his expertise on EPO oppositions and appeals, including cost-effective strategies, hearing preparation, and procedural insights in this in-depth conversation.
From trade secrets to patents, IP plays a vital role in protecting innovation across food science—covering recipes, packaging, and manufacturing in a booming £5.8bn industry.
Recent UPC decisions suggest a shift toward deleting embodiments not covered by amended claims. G 1/25 may confirm this as EPO seeks alignment. Read our analysis and what this means for drafters.
The Düsseldorf UPC rejected a late-filed argument on added matter, reaffirming its strict, front-loaded procedure and the importance of early, complete case preparation.
T 1846/23 shows how G 1/24 is being applied: the EPO rejects narrowing claims via the description alone. As G 1/25 is awaited, the importance of clear drafting is reinforced.
From AI-powered line calls to enhanced fan experiences, tennis is embracing innovation. We explore this transformation and the patent challenges of protecting AI-driven technologies.
The EU’s new Biotech & Biomanufacturing Hub offers funding, R&D, scale-up tools, and IP guidance—supporting SMEs and start-ups across the biotech innovation landscape.
Jonathan Pratt and Angela McCleave join me to reflect on Boult’s standout year – from EQE success to ISO 27001 renewal and major awards.
Should you opt out of the Unified Patent Court? Boult explores the pros and cons, recent case law, and strategic factors for European patent holders in a changing legal landscape.
The European Patent Office (EPO) has insisted upon the adaptation of the description to avoid inconsistencies with amended claims. A Board of Appeal has referred questions on the matter.
